A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: The role of mevalonic acid

British Journal of Pharmacology

Volumn 133, Issue 3, 2001, Pages 406-412

  Stalker, T J ^a   Lefer, A M ^a   Scalia, R ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Endothelium; Leukocyte; Mevalonate; Microcirculation; P selectin; Statins

Indexed keywords

CELL ADHESION MOLECULE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PADGEM PROTEIN; ROSUVASTATIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; MESENTERY BLOOD VESSEL; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR ENDOTHELIUM;

EID: 0034753831     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704070     Document Type: Article

References (27)

1. Discovery, biochemistry and biology of lovastatin
2. An optical doppler intravital velocimeter
3. Inhibition of endothelial-derived nitric oxide promotes P-selectin expression and actions in the rat microcirculation
4. Vascular effects of statins in stroke
5. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
6. Nitric oxide attenuates leukocyte-endothelial interaction via P- selectin in splanchnic ischemia-reperfusion
7. Direct measurement of nitric oxide release from vascular endothelial cells
8. -/- eider transgenic mice
9. Nitric oxide: An endogenous modulator of leukocyte adhesion
10. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
11. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase
12. Targeting rho in cardiovascular disease
13. Nitric oxide: Nature's naturally occurring leukocyte inhibitor
14. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts
15. Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock
16. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms
17. GMP-140: A receptor for neutrophils and monocytes on activated platelets and endothelium
18. Lysophosphatidylcholine promotes P-selectin expression in platelets and endothelial cells. Possible involvement of protein kinase C activation and its inhibition by nitric oxide donors
19. Oxygen radicals induce human endothelial cells to express GMP-140 and bind neutrophils
20. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats
21. The anti-aggregating properties of vascular endothelium: Interactions between prostacyclin and nitric oxide
22. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
23. Lipoxin A4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: Role of P-selectin
24. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
25. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
26. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
27. Time course of coronary vascular endothelial adhesion molecule expression during reperfusion of the ischemic feline myocardium